Achieve Life Sciences Believes It Has The New Chantix

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market.   

smoking cigarette in the hand of young man close up

The only drug that has ever worked particularly well at persuading smokers to put the lighter down is Chantix (varenicline), sold in the EU as Champix. At its peak, in 2019, the α4β2 nicotinic acetylcholine receptor agonist made $1.1bn for its maker, Pfizer Inc. But Chantix went generic in 2021, and last year its sales came to just $4m.

Key Takeaways

  • Cytisinicline has succeeded in two Phase III trials and is heading to the US FDA

Achieve Life Sciences is hoping to pick up the slack with a similarly acting drug, cytisinicline, which the group...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D